Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib Dose Escalation in HER2+ Early Breast Cancer
NCT05154396Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of neratinib in HER2-positive breast cancer, sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
neratinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05154396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05154396.